Pharmaceutical sector: anti-competitive agreements

The CMA is investigating a suspected breach of competition law in the pharmaceutical sector under Chapter I CA98 and Article 101 TFEU.

Case timetable

Date Action
February 2017 (estimate) Decision on next phase of the investigation in light of evidence received to date
September 2016 to January 2017 (estimate) Further information gathering and analysis of information requests
September 2016 Decision to continue with the investigation
August 2016 to September 2016 Investigation and analysis including further information requests and stakeholder meetings
April 2016 to July 2016 Initial investigation: information gathering, including issuance of formal or informal information requests and parties’ responses. CMA analysis and review of parties’ responses to information requests. Potential state of play meetings with parties under investigation
April 2016 Investigation opened


  • The investigation is under Chapter I of the Competition Act 1998 (CA98) and Article 101 of the Treaty on the Functioning of the European Union (TFEU).
  • The CMA has not reached a view as to whether there is sufficient evidence of an infringement of competition law for it to issue a statement of objections to the party/parties under investigation. Not all cases result in the CMA issuing a statement of objections. As a result, it would not be appropriate to include any further estimates of the timing of any later investigative steps at this stage.
  • Changes to the timing of original entries in the case timetable will be made where the estimated timing changes.


Assistant project director

Emma Ngoga (0203 738 6752,

Project director

James MacBeth (0203 738 6958,

Senior responsible officer

Andrew Groves (0203 738 6927,

Help us improve GOV.UK

Don’t include personal or financial information like your National Insurance number or credit card details.